141 related articles for article (PubMed ID: 22506966)
1. Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy.
Nielsen DL; Sengeløv L
Expert Opin Biol Ther; 2012 Jun; 12(6):795-804. PubMed ID: 22506966
[TBL] [Abstract][Full Text] [Related]
2. "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
Loges S; Schmidt T; Carmeliet P
Clin Cancer Res; 2009 Jun; 15(11):3648-53. PubMed ID: 19470735
[TBL] [Abstract][Full Text] [Related]
3. Placental growth factor in cancer.
Dewerchin M; Carmeliet P
Expert Opin Ther Targets; 2014 Nov; 18(11):1339-54. PubMed ID: 25297943
[TBL] [Abstract][Full Text] [Related]
4. PlGF blockade does not inhibit angiogenesis during primary tumor growth.
Bais C; Wu X; Yao J; Yang S; Crawford Y; McCutcheon K; Tan C; Kolumam G; Vernes JM; Eastham-Anderson J; Haughney P; Kowanetz M; Hagenbeek T; Kasman I; Reslan HB; Ross J; Van Bruggen N; Carano RA; Meng YJ; Hongo JA; Stephan JP; Shibuya M; Ferrara N
Cell; 2010 Apr; 141(1):166-77. PubMed ID: 20371352
[TBL] [Abstract][Full Text] [Related]
5. Placental growth factor upregulation is a host response to antiangiogenic therapy.
Bagley RG; Ren Y; Weber W; Yao M; Kurtzberg L; Pinckney J; Bangari D; Nguyen C; Brondyk W; Kaplan J; Teicher BA
Clin Cancer Res; 2011 Mar; 17(5):976-88. PubMed ID: 21343374
[TBL] [Abstract][Full Text] [Related]
6. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects.
Martinsson-Niskanen T; Riisbro R; Larsson L; Winstedt L; Stenberg Y; Pakola S; Stassen JM; Glazer S
Clin Ther; 2011 Sep; 33(9):1142-9. PubMed ID: 21906811
[TBL] [Abstract][Full Text] [Related]
8. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.
Oude Munnink TH; Tamas KR; Lub-de Hooge MN; Vedelaar SR; Timmer-Bosscha H; Walenkamp AM; Weidner KM; Herting F; Tessier J; de Vries EG
J Nucl Med; 2013 Jun; 54(6):929-35. PubMed ID: 23625582
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic agents in cancer therapy.
Lenz HJ
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
[TBL] [Abstract][Full Text] [Related]
10. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
Fischer C; Jonckx B; Mazzone M; Zacchigna S; Loges S; Pattarini L; Chorianopoulos E; Liesenborghs L; Koch M; De Mol M; Autiero M; Wyns S; Plaisance S; Moons L; van Rooijen N; Giacca M; Stassen JM; Dewerchin M; Collen D; Carmeliet P
Cell; 2007 Nov; 131(3):463-75. PubMed ID: 17981115
[TBL] [Abstract][Full Text] [Related]
11. Targeting angiopoietin-2 signaling in cancer therapy.
Eroglu Z; Stein CA; Pal SK
Expert Opin Investig Drugs; 2013 Jul; 22(7):813-25. PubMed ID: 23621441
[TBL] [Abstract][Full Text] [Related]
12. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts.
Taylor AP; Goldenberg DM
Mol Cancer Ther; 2007 Feb; 6(2):524-31. PubMed ID: 17308051
[TBL] [Abstract][Full Text] [Related]
13. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation.
Yoo SA; Yoon HJ; Kim HS; Chae CB; De Falco S; Cho CS; Kim WU
Arthritis Rheum; 2009 Feb; 60(2):345-54. PubMed ID: 19180491
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of placental growth factor in renal cell carcinoma.
Bessho H; Wong B; Huang D; Siew EY; Huang D; Tan J; Ong CK; Tan SY; Matsumoto K; Iwamura M; Teh BT
Anticancer Res; 2015 Jan; 35(1):531-41. PubMed ID: 25550599
[TBL] [Abstract][Full Text] [Related]
15. Human choriocarcinomas: placental growth factor-dependent preclinical tumor models.
Bagley RG; Ren Y; Kurtzberg L; Weber W; Bangari D; Brondyk W; Teicher BA
Int J Oncol; 2012 Feb; 40(2):479-86. PubMed ID: 22075622
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
17. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
18. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence.
Taylor AP; Rodriguez M; Adams K; Goldenberg DM; Blumenthal RD
Int J Cancer; 2003 Jun; 105(2):158-64. PubMed ID: 12673673
[TBL] [Abstract][Full Text] [Related]
19. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.
Van de Veire S; Stalmans I; Heindryckx F; Oura H; Tijeras-Raballand A; Schmidt T; Loges S; Albrecht I; Jonckx B; Vinckier S; Van Steenkiste C; Tugues S; Rolny C; De Mol M; Dettori D; Hainaud P; Coenegrachts L; Contreres JO; Van Bergen T; Cuervo H; Xiao WH; Le Henaff C; Buysschaert I; Kharabi Masouleh B; Geerts A; Schomber T; Bonnin P; Lambert V; Haustraete J; Zacchigna S; Rakic JM; Jiménez W; Noël A; Giacca M; Colle I; Foidart JM; Tobelem G; Morales-Ruiz M; Vilar J; Maxwell P; Vinores SA; Carmeliet G; Dewerchin M; Claesson-Welsh L; Dupuy E; Van Vlierberghe H; Christofori G; Mazzone M; Detmar M; Collen D; Carmeliet P
Cell; 2010 Apr; 141(1):178-90. PubMed ID: 20371353
[TBL] [Abstract][Full Text] [Related]
20. A new weapon for attacking tumor blood vessels.
Semenza GL
N Engl J Med; 2008 May; 358(19):2066-7. PubMed ID: 18463385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
